Shanghai Sine Tianping Pharmaceutical Co., Ltd.

The pharmacokinetic parameters were used as the primary endpoint evaluation indicators to compare the pharmacokinetic behavior of the test preparation Pregabalin sustained-release tablets (manufacturer: Shanghai Xinyi Tianping Pharmaceutical Co., Ltd., specification: 330 mg) and the reference preparation Pregabalin sustained-release tablets (licensed manufacturer: Pf Prism CV, specification: 330 mg, trade name: Lyrica® CR) in healthy subjects after oral administration in the fasting/postprandial state, and evaluate the bioequivalence of the two preparations. At the same time, the safety of the two preparations in healthy subjects was evaluated.

The main purpose of the study is to evaluate the bioequivalence of the test preparation, Cimetidine Tablets produced by Shanghai Xinyi Tianping Pharmaceutical Co., Ltd., and the reference preparation, Cimetidine Tablets (trade name: Tagamet HB®) produced by Medtech Products Inc. in healthy subjects; The secondary purpose of the study is to observe the safety of the test preparation and the reference preparation in healthy subjects.

The absorption rate and extent of Nifedipine sustained-release tablets (II) and Adalat®-L20 were evaluated in healthy male and female subjects under fasting conditions to evaluate whether the two preparations are bioequivalent. At the same time, the safety of the test preparation Nifedipine sustained-release tablets (II) and the reference preparation Adalat®-L20 in healthy Chinese subjects was observed.